Amyloid plaques

Researchers from Columbia University, including a Turkish scientist, have discovered a genetic change that reduces the risk of Alzheimer's by 71 percent.

The approval by the US Food and Drug Administration last Thursday of the antibody treatment Leqembi, which significantly slows the progression of Alzheimer's in its early stages, has given hope to millions of patients and their families. 

The drug is the fruit of the collaboration between American biotechnology company Biogen and Japan's Eisai.